Parasitic Infections in HIV-Infected Patients

  • Authors: José M. Miró, MD, PhD; Miriam J. Álvarez-Martínez, MD, PhD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/20/21 (What's New)

Summary

  • Guidelines on opportunistic infections indicate that benznidazole and nifurtimox are useful for reducing parasitemia and preventing clinical manifestations in congenital, acute phases and reactivations of Chagas disease (Table 11) (Management Guidelines)[CDC OI] (Management Guidelines)[GESIDA OI]
  • Benznidazole is approved by the FDA for children 2-12 years of age but is commercially available for patients with Chagas disease without limitation of age. Nifurtimox is approved by the FDA for children from birth to 18 years of age
  • Optimal duration of therapy has not been established in patients with HIV

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.